Photo from Mohamed Benlazar/X
Dec 10, 2024, 19:19
Mohamed Benlazar: CPX-351 vs FLAG-Ida in younger adult patients with AML/MDS and MDS-related gene mutations
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:
“CPX-351 vs FLAG-Ida in younger adult patients with newly diagnosed high-risk AML/MDS and MDS-related gene mutations. ASH24.”
More posts featuring Mohamed Benlazar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 15:50
May 10, 2025, 15:35
May 10, 2025, 15:01
May 10, 2025, 15:01
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57